Pirtobrutinib(一种高选择性非共价BTK抑制剂)治疗复发/难治性边缘区淋巴瘤:1/2期BRUIN研究
BRUIN研究评估了Pirtobrutinib在复发/难治性边缘区淋巴瘤(R/R MZL)患者中的安全性和有效性。36例患者中客观缓解率(ORR)为55.6%,中位缓解持续时间(DOR)17.8个月,中位无进展生存期(PFS)16.6个月,且耐受性良好。
要点
- Pirtobrutinib在经多线治疗的R/R MZL中ORR达55.6%,包括8.3%完全缓解。
- 既往接受过共价BTK抑制剂治疗的患者ORR为53.8%。
- 因治疗中出现的不良事件导致永久停药的比例为11.1%。
核心结论
- Pirtobrutinib在经多线治疗的R/R MZL患者中显示出有前景的疗效和安全性,包括既往接受过共价BTK抑制剂的患者。
研究设计与样本
- 1/2期BRUIN研究,纳入36例复发/难治性边缘区淋巴瘤患者(结外n=6,结节型n=17,脾型n=13),中位年龄68岁,中位既往治疗线数3线。
主要发现
- 客观缓解率(ORR)为55.6%(95%CI 38.1-72.1),其中完全缓解3例(8.3%),部分缓解17例(47.2%)。
- 中位缓解持续时间(DOR)为17.8个月(95%CI 7.4-不可估计),中位无进展生存期(PFS)为16.6个月(95%CI 9.0-22.1)。
- 中位随访32.4个月(IQR 28.0-41.3)时,中位总生存期(OS)不可估计(95%CI 29.5-不可估计)。
- 既往接受过共价BTK抑制剂治疗的患者ORR为53.8%(95%CI 33.4-73.4)。
- 剂量减少见于4例(11.1%),因治疗中出现的不良事件永久停药4例(11.1%)。
临床怎么用
- 对于经多线治疗(包括共价BTK抑制剂)失败的R/R MZL患者,Pirtobrutinib提供了一种有效且耐受性良好的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Marginal zone lymphoma (MZL) is a group of indolent B-cell malignancies with a remitting and relapsing course. For systemic disease, available first-line therapies include anti-CD20 antibody as monotherapy or in combination with chemotherapy (chemoimmunotherapy), with second-line options including covalent Bruton tyrosine kinase inhibitors (cBTKi). However, management of relapsed and refractory (R/R) MZL remains challenging. Pirtobrutinib, a highly selective, noncovalent BTKi has shown promising efficacy and tolerability in poor-prognosis B-cell malignancies following prior therapy, including cBTKi. Here, we report the safety and efficacy of pirtobrutinib in MZL from the phase 1/2 BRUIN study. Endpoints included investigator-assessed objective response rate (ORR) by Lugano 2014 criteria, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Among 36 patients with R/R MZL (extranodal [n = 6]; nodal [n = 17]; splenic [n = 13]), median age was 68 years (range, 22-83) and median prior lines of therapy were 3 (range, 2-10). The ORR was 55.6% (95% confidence interval [CI], 38.1- 72.1), including 3 (8.3%) complete responses and 17 (47.2%) partial responses. Median DOR was 17.8 months (95% CI, 7.4 to nonestimable [NE]), and median PFS was 16.6 months (95% CI, 9.0-22.1). With median follow-up of 32.4 months (IQR, 28.0-41.3), median OS was NE (95% CI, 29.5-NE). The ORR for patients with prior cBTKi therapy was 53.8% (95% CI, 33.4-73.4). Pirtobrutinib was well tolerated with dose reductions in 4 patients (11.1%) and permanent discontinuation due to treatment emergent adverse events in 4 patients (11.1%). Pirtobrutinib showed promising efficacy and safety in patients with heavily pretreated R/R MZL, including prior cBTKi. This trial was registered at www.clinicaltrials.gov as #NCT03740529.
引用
- Patel K, Vose JM, Nasta SD, et al. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. Blood Adv. 2026. PMID: 41544219. doi:10.1182/bloodadvances.2025017489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。